CHENNAI: Biocon Limited posted a mixed set of numbers for the quarter ended June 30, 2025, with strong revenue growth offset ...

The biopharma company's stock fell as much as 3.60 per cent during the day to ₹331 per share, the lowest level since June 6 ...

Biocon Ltd. reported a 95% fall in net profit for the first quarter of financial year 2026. The pharma company reported a consolidated bottom line of Rs 31.4 crore, a sharp fall from net profit of Rs ...

The company is also focused on strategic capital deployment. It has already invested in GLP-1 drug substance and drug product ...

Shares of Biocon declined by 2.72% to Rs 334.00 in Monday's early trading session. The decline positions the stock among the ...

Biocon’s S&P Global ESG score was 63 versus 52 previously, placing it among the Top 10 global biotechnology companies from within the 300 companies that were assessed, it stated.

Biocon Q1 FY25 Results 2024: The results for Biocon’s Q1 results for FY24 will also be published on both the Bombay Stock Exchange (BSE) and National Stock Exchange (NSE) websites.

Biocon is in the process of securing investments to retire the mezzanine financing, post deal closure. Post the conclusion of the Viatris and Serum transactions, Biocon Limited’s stake in Biocon ...

Biocon’s subsidiary, Biocon Biologics, is under investigation in a bribery case involving the country’s joint drugs controller and a recent waiver of phase III clinical trials granted for one ...

Mumbai: The government has waived key Phase 3 clinical trials on Biocon’s drug Itolizumab, the first biologic to have received approval for treating Covid-19 patients, raising questions by ...

Indian biopharmaceutical firm Biocon is likely to list its key biosimilars business by March 2026 and aims for double-digit share in its core U.S. market for its new launches, a top executive told ...

Biocon Ltd posted strong net profit and revenue figures for the first quarter of FY23. Its net profit increased by 71 per cent to ₹ 144 crore from ₹84 crore in June 2021. The pharmaceutical ...